RecruitingPhase 1Phase 2NCT06557265

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease

Sponsor

Nkarta, Inc.

Enrollment

120 participants

Start Date

Jun 13, 2024

Study Type

INTERVENTIONAL

Conditions

Lupus Nephritis Primary Membranous Nephropathy

Summary

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Fludarabine, Cyclophosphamide and a drug called NKX019 for people with lupus nephritis and primary membranous nephropathy. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNKX019

NKX019 is an investigational allogeneic CD19-Directed CAR NK

DRUGFludarabine, Cyclophosphamide

For Lymphodepletion

Locations(19)

Nkarta Investigational Site

Little Rock, Arkansas, United States

Nkarta Investigational Site

Tustin, California, United States

Nkarta Investigational Site

Gainesville, Florida, United States

Nkarta Investigational Site

Miami, Florida, United States

Nkarta Investigational Site

Plantation, Florida, United States

Nkarta Investigational Site

Tampa, Florida, United States

Nkarta Investigational Site

Atlanta, Georgia, United States

Nkarta Investigational Site

Chicago, Illinois, United States

Nkarta Investigational Site

New Orleans, Louisiana, United States

Nkarta Investigational Site

Worcester, Massachusetts, United States

Nkarta Investigational Site

Ann Arbor, Michigan, United States

Nkarta Investigational Site

Summit, New Jersey, United States

Nkarta Investigational Site

New York, New York, United States

Nkarta Investigational Site

Stony Brook, New York, United States

Nkarta Investigational Site

Syracuse, New York, United States

Nkarta Investigational Site

Dallas, Texas, United States

Nkarta Investigational Site

Houston, Texas, United States

Nkarta Investigational Site

Parkville, Victoria, Australia

Nkarta Investigational Site

Manati, Puerto Rico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06557265

Related Trials

Wellness & Workforce Solution for Lupus/Lupus Nephritis

NCT062171071 location

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT0709684343 locations

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

NCT0671188741 locations

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289103 locations